NCT03581903View on ClinicalTrials.gov

A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

September 14, 2018

Study Completion Date

February 6, 2019

Conditions

Influenza

Interventions

BIOLOGICAL

H7N3 pLAIV

Approximately 10\^7.0 fluorescent focus units (FFUs) administered intranasally by an Accuspray device

BIOLOGICAL

H7N9 pIIV

30 micrograms administered by intramuscular (IM) injection

Trial Locations (1)

14642

University of Rochester Medical Center Vaccine Research Unit (Outpatient), Rochester

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03581903 - A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine | Biotech Hunter | Biotech Hunter